Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nycomed issues profit warning as US prices tumble

This article was originally published in Clinica

Executive Summary

An intensification of the US contrast media price war has prompted Nycomed to issue a warning that full-year profits are likely to shrink by almost 20%. The demerged pharmaceutical and diagnostic arm of the Norwegian Hafslund Nycomed group expects 1996 profits to be "closer to the 1994 than the 1995 level". Nycomed Imaging reported operating profits of NKr 2,329 million ($353 million) for 1995, up 39.6% on the previous year (see Clinica No 693, p 9).

You may also be interested in...



STRENGTH Results May Weaken Chances For Omega-3 Fatty Acid Heart Health Claims

Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.

FDA To Combo Product Sponsors: Consider Traditional Pathways Before Asking For Meeting

In a final guidance from the US agency, regulators say most combination product questions are best resolved through traditional pathways and noted that initiating a so-called combination product agreement meeting may be unproductive.

Conquering Metabesity: Expert Panel Discusses Roadmap To Find Solutions

Metabesity is a complex issue that will require a multi-disciplinary approach, concerted effort and clear regulatory pathway to achieve solutions.

Topics

UsernamePublicRestriction

Register

ID1132679

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel